Michael Kalos, Ph.D.

Share Event

Loading Events

Wait! A Note on Registration:

We’ve launched Cvent—our new events platform!

Registration for any event with a start date after Sept. 28 now requires a CFA Institute account.

I don’t have a CFA Institute account

  • No problem! You’ll have the chance to create one prior to registration.

I already have a CFA Institute account

  • Great! Be sure to use your existing credentials at registration.
Cvent Transition Guide

Michael Kalos, Ph.D., is a member of Lilly’s Research Oncology Division, where he leads preclinical and translational efforts in Cancer Immunotherapy. Dr. Kalos is a recognized international key thought leader in the fields of immunotherapy and biomarkers, with over 20 years experience spanning biotech, academia, and big pharma. He has authored multiple high-impact primary and review articles as well as book chapters in the field of cancer immunotherapy, has been an invited speaker at national and international scientific meetings, is a member of institutional and corporate scientific advisory boards, and steering committees for international immunotherapy societies and working groups.